(excerpt) 2006-03-13-29 - Circare

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
13
of Lethbridge. He is a neuroscientist. And he
wasn't willing to run a clinical trial on the
product, but he was willing to basically give them
the advice that they needed in structuring their own
informal trial, so, he basically explained to them,
Well, use these rating scales and collect the data
this way. And then once that was done, he crunched
the numbers for them. And the numbers were
statistically startling.
So, he contacts Dr. Bonnie Kaplan, from the
University of Calgary, and basically shares this
information with her and through that, now Dr.
Kaplan is looking at that. She decides to run a
small clinical trial at the University of Calgary,
and this is on these four products that are off the
shelf. The problem is, is halfway through the trial
it became apparent that one of those products was
going up and down in, I guess its purity or its
potency, and you can't be running a trial and have
the ingredients of your trial be inconsistent. So,
that trial was scrubbed.
And so, now, it became apparent to Mr. Stephan
and Mr. Hardy, and aside from the fact that people
that were on this protocol were also noticing, Just
wait a second, this isn't as good, that they had to
contract with somebody to manufacture to ensure that
it was reliable. And so, basically what they did is